Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies

Radu Marches, Pavitra Chakravarty, Inga H. Musselman, Pooja Bajaj, Robert N. Azad, Paul Pantano, Rockford K. Draper, Ellen S. Vitetta

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

CD22 is broadly expressed on human B cell lymphomas. Monoclonal anti-CD22 antibodies alone, or coupled to toxins, have been used to selectively target these tumors both in SCID mice with xenografted human lymphoma cell lines and in patients with B cell lymphomas. Single-walled carbon nanotubes (CNTs) attached to antibodies or peptides represent another approach to targeting cancer cells. CNTs convert absorbed near-infrared (NIR) light to heat, which can thermally ablate cells that have bound the CNTs. We have previously demonstrated that monoclonal antibodies (MAbs) noncovalently coupled to CNTs can specifically target and kill cells in vitro. Here, we describe the preparation of conjugates in which the MAbs are covalently conjugated to the CNTs. The specificity of both the binding and NIR-mediated killing of the tumor cells by the MAb-CNTs is demonstrated by using CD22+CD25- Daudi cells, CD22 2CD25+ phytohemagglutinin-activated normal human peripheral blood mononuclear cells, and CNTs covalently modified with either anti-CD22 or anti-CD25. We further demonstrate that the stability and specificity of the MAb-CNT conjugates are preserved following incubation in either sodium dodecyl sulfate or mouse serum, indicating that they should be stable for in vivo use.

Original languageEnglish (US)
Pages (from-to)2970-2977
Number of pages8
JournalInternational Journal of Cancer
Volume125
Issue number12
DOIs
StatePublished - Dec 15 2009

Fingerprint

Carbon Nanotubes
Hot Temperature
Monoclonal Antibodies
Neoplasms
B-Cell Lymphoma
SCID Mice
Phytohemagglutinins
Sodium Dodecyl Sulfate
Anti-Idiotypic Antibodies
Lymphoma
Blood Cells
Light
Cell Line
Peptides
Antibodies
Serum

Keywords

  • Cancer therapy
  • Monoclonal antibody
  • Near-infrared thermal ablation
  • Single-walled carbon nanotube

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies. / Marches, Radu; Chakravarty, Pavitra; Musselman, Inga H.; Bajaj, Pooja; Azad, Robert N.; Pantano, Paul; Draper, Rockford K.; Vitetta, Ellen S.

In: International Journal of Cancer, Vol. 125, No. 12, 15.12.2009, p. 2970-2977.

Research output: Contribution to journalArticle

Marches, Radu ; Chakravarty, Pavitra ; Musselman, Inga H. ; Bajaj, Pooja ; Azad, Robert N. ; Pantano, Paul ; Draper, Rockford K. ; Vitetta, Ellen S. / Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies. In: International Journal of Cancer. 2009 ; Vol. 125, No. 12. pp. 2970-2977.
@article{8d7069f52fb5426d962a52d843c63cf7,
title = "Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies",
abstract = "CD22 is broadly expressed on human B cell lymphomas. Monoclonal anti-CD22 antibodies alone, or coupled to toxins, have been used to selectively target these tumors both in SCID mice with xenografted human lymphoma cell lines and in patients with B cell lymphomas. Single-walled carbon nanotubes (CNTs) attached to antibodies or peptides represent another approach to targeting cancer cells. CNTs convert absorbed near-infrared (NIR) light to heat, which can thermally ablate cells that have bound the CNTs. We have previously demonstrated that monoclonal antibodies (MAbs) noncovalently coupled to CNTs can specifically target and kill cells in vitro. Here, we describe the preparation of conjugates in which the MAbs are covalently conjugated to the CNTs. The specificity of both the binding and NIR-mediated killing of the tumor cells by the MAb-CNTs is demonstrated by using CD22+CD25- Daudi cells, CD22 2CD25+ phytohemagglutinin-activated normal human peripheral blood mononuclear cells, and CNTs covalently modified with either anti-CD22 or anti-CD25. We further demonstrate that the stability and specificity of the MAb-CNT conjugates are preserved following incubation in either sodium dodecyl sulfate or mouse serum, indicating that they should be stable for in vivo use.",
keywords = "Cancer therapy, Monoclonal antibody, Near-infrared thermal ablation, Single-walled carbon nanotube",
author = "Radu Marches and Pavitra Chakravarty and Musselman, {Inga H.} and Pooja Bajaj and Azad, {Robert N.} and Paul Pantano and Draper, {Rockford K.} and Vitetta, {Ellen S.}",
year = "2009",
month = "12",
day = "15",
doi = "10.1002/ijc.24659",
language = "English (US)",
volume = "125",
pages = "2970--2977",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies

AU - Marches, Radu

AU - Chakravarty, Pavitra

AU - Musselman, Inga H.

AU - Bajaj, Pooja

AU - Azad, Robert N.

AU - Pantano, Paul

AU - Draper, Rockford K.

AU - Vitetta, Ellen S.

PY - 2009/12/15

Y1 - 2009/12/15

N2 - CD22 is broadly expressed on human B cell lymphomas. Monoclonal anti-CD22 antibodies alone, or coupled to toxins, have been used to selectively target these tumors both in SCID mice with xenografted human lymphoma cell lines and in patients with B cell lymphomas. Single-walled carbon nanotubes (CNTs) attached to antibodies or peptides represent another approach to targeting cancer cells. CNTs convert absorbed near-infrared (NIR) light to heat, which can thermally ablate cells that have bound the CNTs. We have previously demonstrated that monoclonal antibodies (MAbs) noncovalently coupled to CNTs can specifically target and kill cells in vitro. Here, we describe the preparation of conjugates in which the MAbs are covalently conjugated to the CNTs. The specificity of both the binding and NIR-mediated killing of the tumor cells by the MAb-CNTs is demonstrated by using CD22+CD25- Daudi cells, CD22 2CD25+ phytohemagglutinin-activated normal human peripheral blood mononuclear cells, and CNTs covalently modified with either anti-CD22 or anti-CD25. We further demonstrate that the stability and specificity of the MAb-CNT conjugates are preserved following incubation in either sodium dodecyl sulfate or mouse serum, indicating that they should be stable for in vivo use.

AB - CD22 is broadly expressed on human B cell lymphomas. Monoclonal anti-CD22 antibodies alone, or coupled to toxins, have been used to selectively target these tumors both in SCID mice with xenografted human lymphoma cell lines and in patients with B cell lymphomas. Single-walled carbon nanotubes (CNTs) attached to antibodies or peptides represent another approach to targeting cancer cells. CNTs convert absorbed near-infrared (NIR) light to heat, which can thermally ablate cells that have bound the CNTs. We have previously demonstrated that monoclonal antibodies (MAbs) noncovalently coupled to CNTs can specifically target and kill cells in vitro. Here, we describe the preparation of conjugates in which the MAbs are covalently conjugated to the CNTs. The specificity of both the binding and NIR-mediated killing of the tumor cells by the MAb-CNTs is demonstrated by using CD22+CD25- Daudi cells, CD22 2CD25+ phytohemagglutinin-activated normal human peripheral blood mononuclear cells, and CNTs covalently modified with either anti-CD22 or anti-CD25. We further demonstrate that the stability and specificity of the MAb-CNT conjugates are preserved following incubation in either sodium dodecyl sulfate or mouse serum, indicating that they should be stable for in vivo use.

KW - Cancer therapy

KW - Monoclonal antibody

KW - Near-infrared thermal ablation

KW - Single-walled carbon nanotube

UR - http://www.scopus.com/inward/record.url?scp=72449201252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449201252&partnerID=8YFLogxK

U2 - 10.1002/ijc.24659

DO - 10.1002/ijc.24659

M3 - Article

C2 - 19536775

AN - SCOPUS:72449201252

VL - 125

SP - 2970

EP - 2977

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -